The USC-UCLA Drug-Induced Liver Injury Clinical Center (CC) application in response to RFA-DK-13-003 "Continuation and Expansion of the Drug Induced Liver Injury Network (DILIN)" hopes to continue to participate with the other CCs to advance the scientific knowledge and clinical evaluation of DILI. Our application will continue to combine the only two medical schools in Los Angeles County allowing us to continue to uniquely capture and enroll DILI cases into the Networks database supervised by the Data Coordinating Center (DCC). The 9.3 M residents of Los Angeles County (2011) are an unmatched resource composed of the most ethnically diverse population in the United States. Our application continues to utilize the expertise and talents from USC and UCLA medical centers. The enrollment of a large number of bona fide and ill patients with close follow up has demonstrated our CC's ability to capture DILIN cases in this diverse populations.
The Specific Aims for the continuation of the USC-UCLA DILI CC are to: 1) Continue enrollment of high quality cases with collection of disease controls and acute cases for mechanistic studies;2) Detailed analysis of cholestatic DILI due to HDS using genetic and serum analysis;3) Immunological surveying of acute DILI cases compared with disease control to identify potential mechanism of liver injury;4) Proteomic studies in acute cases of hepatocellular to identify mechanism of disease;and 5) Support of DILIN effort to develop assessment instruments and a treatment trial.

Public Health Relevance

Prescription and non-prescription medications, which include vitamins, herbal preparations, or, non-traditional forms of medicines, can very rarely cause significant liver injury. Because these events are so rare, the NIH has established a network of investigators to identify these rare causes of liver injury so that a shared database can be used for future studies. The USC-UCLA Drug-Induced Liver Injury Clinical Center wishes to continue to work with this established network to better understand causes of liver injury due to these agents.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-N (M7))
Program Officer
Serrano, Jose
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Internal Medicine/Medicine
Schools of Medicine
Los Angeles
United States
Zip Code
Fontana, Robert J; Hayashi, Paul H; Gu, Jiezhun et al. (2014) Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147:96-108.e4
Kleiner, David E; Chalasani, Naga P; Lee, William M et al. (2014) Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59:661-70
Orman, Eric S; Conjeevaram, Hari S; Vuppalanchi, Raj et al. (2011) Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 9:517-523.e3